Best & Worst Biotech Stocks: ImmunoCellular, Immunomedics, MannKind, Celldex, ACADIA, NeoStem, BioCryst, Rexahn, ZIOPHARM, Inovio, XOMA, InterMune, Alexion

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) rallied 15.11% on Monday after a Bloomberg report said Roche (RHHBY) is seeking financing for an acquisition offer for Alexion (ALXN).

The report lifted shares of Immunomedics, Inc. (NASDAQ:IMMU), MannKind Corporation (NASDAQ:MNKD) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) as these were among several biotech stocks encouraged by the signs that large medical players are in a buying mood.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) surged 9.68%, hitting new high after receiving positive mention a Seeking Alpha blog post, suggesting it as an undervalued small-cap stock.

NeoStem Inc (NYSEMKT:NBS) gained amid news that it has signed agreements with the University of California, San Francisco and the laboratories of Jeffrey Bluestone, PhD, and Qizhi Tang, PhD, to work together on the development of human Regulatory T cells (“Tregs”) for the treatment of type 1 diabetes (“T1D”), steroid resistant asthma, and organ transplant rejection.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) jumped again after disclosing that the Biomedical Advanced Research and Development Authority (BARDA/HHS) has released funding under the current $234.8 million contract to enable completion of a New Drug Application (NDA) filing for intravenous (i.v.) peramivir. The company is looking for an indication for the treatment of acute uncomplicated influenza and expects to submit the peramivir NDA by the end of 2013.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) surged 9.01% after revealing that Teva Pharmaceutical Industries has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for RX-3117, a novel oral small molecule chemotherapy agent, under a June 2009 Research and Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd. for RX-3117.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) extended three-day winning streak after its presentation at the 8th Annual JMP Securities Healthcare Conference in St. Regis Hotel, New York.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) rose 4.88%, gaining again after peer-reviewed publication of results from Pennvax-B trials with Cellectra device.

XOMA Corp (NASDAQ:XOMA) advanced 4.64%, hitting new high after a Form SC 13D/A was filed with the SEC on Friday.

InterMune Inc (NASDAQ:ITMN) extended gains after Bloomberg reported the European Medicines Agency appealed rulings that blocked it from releasing clinical-trial data from AbbVie Inc. (ABBV) and biotechnology company InterMune Inc. at the European Union’s highest court. The rally may also have something to with the Alexion report.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) retreated 5.54% after sharp gains on Friday on reports that Roche Holding AG  is seeking financing to take over the company.